"The U.S. Food and Drug Administration today approved Orbactiv (oritavancin), a new antibacterial drug to treat adults with skin infections.
Orbactiv is approved to treat patients with acute bacterial skin and skin structure infections (ABSS"...
Sklice Side Effects Center
Medical Editor: Charles Patrick Davis, MD, PhD
Sklice (ivermectin) Lotion is a pediculicide indicated for the topical treatment of head lice infestations in patients six months of age and older. Sklice is available as a generic termed ivermectin. Most common adverse reactions are conjunctivitis, ocular hyperemia, eye irritation, dandruff, dry skin, and skin burning sensation.
Sklice is dosed in single-use tubes. Sklice should be applied to dry hair in an amount sufficient (up to 1 tube) to thoroughly coat the hair and scalp. Sklice should be rinsed out of the hair after 10 minutes and any unused portion of Sklice should be discarded. Serious side effects include ingestion by children; this drug should only be administered by an adult. There are no adequate and well-controlled studies with Sklice Lotion in pregnant women. Sklice Lotion should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Before using Sklice lotion, women should tell their healthcare providers if they are pregnant or planning to become pregnant, and if they are breastfeeding or planning to breastfeed. It is not known if Sklice passes into breast milk. This drug is used in pediatric populations that are six months or older.
Our Sklice Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Sklice FDA Prescribing Information: Side Effects
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
The data described below reflect exposure to a single 10 minute treatment of SKLICE Lotion in 379 patients, ages 6 months and older, in placebo-controlled trials. Of these subjects, 47 subjects were age 6 months to 4 years, 179 subjects were age 4 to 12 years, 56 subjects were age 12 to 16 years and 97 subjects were age 16 or older. Adverse reactions, reported in less than 1% of subjects treated with SKLICE Lotion, include conjunctivitis, ocular hyperemia, eye irritation, dandruff, dry skin, and skin burning sensation.
Read the entire FDA prescribing information for Sklice (Ivermectin)
Additional Sklice Information
- Sklice Drug Interactions Center: ivermectin top
- Sklice Side Effects Center
- Sklice FDA Approved Prescribing Information including Dosage
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.